Targeted Protein Aggregation Takes on KRAS

KRAS is a key oncogenic driver that is notoriously difficult to drug. Our latest paper in the Proceedings of the National Academy of Sciences describes using the targeted protein aggregation technology, invented in our lab, to induce the aggregation of KRAS.

Treatment with the anti-KRAS Pept-in led to the downregulation of the PI3K/AKT pathway, apoptosis, and eventually, the death of cancer cells. The anti-KRAS Pept-in also proved effective in a mouse lung cancer allograft model – without adverse effects to the host!

Read the paper in full on the PNAS website